Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas

Authors :: Robert Lowsky
Richard T. Hoppe
Michael S. Khodadoust
Kathleen A McDonald
Michael Patvin Chu
Steven R. Long
Debra K. Czerwinski
Ronald Levy
Ranjana H. Advani
Holbrook E Kohrt
Source :: Journal of Clinical Oncology. 33:TPS8604-TPS8604
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: TPS8604 Background: Immunotherapy is a promising treatment modality for low grade non-Hodgkin’s lymphomas. SD-101 (Dynavax Technologies) is an immunostimulatory synthetic CpG molecule that activate...

Subjects :: Cancer Research
business.industry
medicine.medical_treatment
Immunotherapy
medicine.anatomical_structure
Phase i ii
Oncology
CpG site
immune system diseases
Treatment modality
hemic and lymphatic diseases
Immunology
medicine
Anti-CTLA-4 Monoclonal Antibody
business
B cell

Full Text Access

Tools